0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead drug candidate, with OncoNano eligible for upfront, milestone and royalty payments and up to US$300.00 million if Gilead adds a second target. This collaboration underscores Gilead's continued push to enhance drug delivery and efficacy in its pipeline, potentially reinforcing its focus on innovative therapies. Now we'll examine how this ON-BOARD collaboration could influence Gilead's investment narrative built around HIV strength and pipeline diversification. AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. To own Gilead, you generally need to believe its durable HIV franchise can keep underpinning cash flows while newer therapies in oncology and other areas broaden the story. The OncoNano ON-BOARD collaboration looks incremental rather than a near term game changer, with the main catalyst still centered on exe [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead drug candidate, with OncoNano eligible for upfront, milestone and royalty payments and up to US$300.00 million if Gilead adds a second target. This collaboration underscores Gilead's continued push to enhance drug delivery and efficacy in its pipeline, potentially reinforcing its focus on innovative therapies. Now we'll examine how this ON-BOARD collaboration could influence Gilead's investment narrative built around HIV strength and pipeline diversification. AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. To own Gilead, you generally need to believe its durable HIV franchise can keep underpinning cash flows while newer therapies in oncology and other areas broaden the story. The OncoNano ON-BOARD collaboration looks incremental rather than a near term game changer, with the main catalyst still centered on exe [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS